Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NHS Scotland

- PMLiVE

Novartis’ Consentyx granted approval by SMC to treat hidradenitis suppurativa

The drug is available in Scotland on the NHS to treat the chronic inflammatory condition

- PMLiVE

Bristol Myers Squibb’s Sotyktu accepted by SMC for plaque psoriasis

More than 133,520 people in Scotland are affected by the inflammatory condition

- PMLiVE

Janssen reveals positive results for nipocalimab in rheumatoid arthritis

About 13 million people worldwide are affected by the chronic inflammatory disease

- PMLiVE

SMC enables access to Kyowa Kirin’s Crysvita for adults with rare genetic disease

XLH is a life-long genetic disease that causes abnormalities in the bones, muscles and joints

- PMLiVE

MSD’s Keytruda plus chemotherapy approved in Scotland for advanced cervical cancer

There were around 604,000 new cases and 342,000 deaths in 2020 from cervical cancer

- PMLiVE

Gilead and EVOQ Therapeutics partner in deal potentially worth over $650m

The companies will focus on developing therapies for rheumatoid arthritis and lupus

- PMLiVE

AbbVie receives extended SMC recommendation for Rinvoq in rheumatoid arthritis patients

In Scotland, there are around 44,000 people living with the progressive autoimmune disease

- PMLiVE

NHS Scotland to offer Jyseleca for patients with moderate rheumatoid arthritis

More than 40,000 people in Scotland live with RA and an estimated 35% of those will have moderate disease activity

- PMLiVE

Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis

Rheumatoid arthritis is a long-term condition that causes painful swelling and stiffness in the joints

- PMLiVE

AbbVie’s Rinvoq accepted by SMC for atopic dermatitis

Scotland is the first nation in the UK to approve NHS access for the drug

- PMLiVE

SMC approves Parkinson’s disease treatment Ongentys

The once-daily additional oral treatment for patients living with Parkinson’s disease is now accepted for use within NHS Scotland

Covid-19: how is it affecting prescribing patterns?

Oli Hudson, Content Director at Wilmington Healthcare, analyses prescribing data in three key disease areas

Wilmington Healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links